Wuhan University, Hubei

Findings describe new data in hepatitis B therapy research

Published in Health Business Week, November 18th, 2005

Hepatitis b therapy research advances have been reported from the People's Republic of China, People's Republic of China and South Africa.

Study 1: Dual small interfering RNA attacks hepatitis B infection on two fronts.

According to recent research from the People's Republic of China, "RNA interference (RNAi) has been successfully applied in suppression of hepatitis B virus (HBV) replication. To circumvent the problem that mutation in HBV genome may result in resistance when siRNA is further developed as an antiviral drug, in this study, we established a dual small interfering RNA (siRNA) expression system, which could simultaneously express two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2005-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry